e-learning
resources
Virtual 2021
06.09.2021
Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
T. Yamaya (Yokohama city, Japan), E. Hagiwara (Yokohama city, Japan), T. Baba (Yokohama city, Japan), T. Iwasawa (Yokohama city, Japan), T. Ogura (Yokohama city, Japan)
Source:
Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Session:
Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Session type:
E-poster
Number:
2254
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Yamaya (Yokohama city, Japan), E. Hagiwara (Yokohama city, Japan), T. Baba (Yokohama city, Japan), T. Iwasawa (Yokohama city, Japan), T. Ogura (Yokohama city, Japan). Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. 2254
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
New antifibrotic drugs: will interstitial diseases patients still need lung transplantation?
Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs
Year: 2020
The mechanisms of antiinflammatory effect of mucolytic therapy
Source: International Congress 2014 – Predictors
Year: 2014
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy
Source: Annual Congress 2013 –Sarcoidosis
Year: 2013
Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode
Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure
Year: 2018
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients
Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections
Year: 2011
Monitoring anti-inflammatory treatments in IPF and related disorders
Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments
Year: 2004
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients?
Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017
Year: 2017
Mucolytics and anti-inflammatory lung treatments
Source: ERS course 2015
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept